262 related articles for article (PubMed ID: 24785233)
1. Comparative evaluation of the tolerability of cefazolin and nafcillin for treatment of methicillin-susceptible Staphylococcus aureus infections in the outpatient setting.
Youngster I; Shenoy ES; Hooper DC; Nelson SB
Clin Infect Dis; 2014 Aug; 59(3):369-75. PubMed ID: 24785233
[TBL] [Abstract][Full Text] [Related]
2. Retrospective Analysis of Adverse Drug Events Between Nafcillin Versus Cefazolin for Treatment of Methicillin-Susceptible
Chan L; Chan-Tompkins NH; Como J; Guarascio AJ
Ann Pharmacother; 2020 Jul; 54(7):662-668. PubMed ID: 31888347
[No Abstract] [Full Text] [Related]
3. Comparison of Nafcillin and Cefazolin for the Treatment of Methicillin-Susceptible Staphylococcus aureus Bacteremia.
Twilla JD; Algrim A; Adams EH; Samarin M; Cummings C; Finch CK
Am J Med Sci; 2020 Jul; 360(1):35-41. PubMed ID: 32376001
[TBL] [Abstract][Full Text] [Related]
4. Comparative outcomes of cefazolin versus nafcillin for methicillin-susceptible Staphylococcus aureus bacteraemia: a prospective multicentre cohort study in Korea.
Lee S; Song KH; Jung SI; Park WB; Lee SH; Kim YS; Kwak YG; Kim YK; Kiem SM; Kim HI; Kim ES; Park KH; Kim NJ; Jang HC; Kim HB;
Clin Microbiol Infect; 2018 Feb; 24(2):152-158. PubMed ID: 28694202
[TBL] [Abstract][Full Text] [Related]
5. Cefazolin versus Nafcillin for Methicillin-Sensitive Staphylococcus aureus Bloodstream Infection in a California Tertiary Medical Center.
Pollett S; Baxi SM; Rutherford GW; Doernberg SB; Bacchetti P; Chambers HF
Antimicrob Agents Chemother; 2016 Aug; 60(8):4684-9. PubMed ID: 27216053
[TBL] [Abstract][Full Text] [Related]
6. A comparison of safety and outcomes with cefazolin versus nafcillin for methicillin-susceptible Staphylococcus aureus bloodstream infections.
Miller MA; Fish DN; Barber GR; Barron MA; Goolsby TA; Moine P; Mueller SW
J Microbiol Immunol Infect; 2020 Apr; 53(2):321-327. PubMed ID: 30190234
[TBL] [Abstract][Full Text] [Related]
7. Nafcillin versus cefazolin for the treatment of methicillin-susceptible Staphylococcus aureus bacteremia.
Monogue ML; Ortwine JK; Wei W; Eljaaly K; Bhavan KP
J Infect Public Health; 2018; 11(5):727-731. PubMed ID: 29526442
[TBL] [Abstract][Full Text] [Related]
8. Comparative Effectiveness of Cefazolin Versus Nafcillin or Oxacillin for Treatment of Methicillin-Susceptible Staphylococcus aureus Infections Complicated by Bacteremia: A Nationwide Cohort Study.
McDanel JS; Roghmann MC; Perencevich EN; Ohl ME; Goto M; Livorsi DJ; Jones M; Albertson JP; Nair R; O'Shea AMJ; Schweizer ML
Clin Infect Dis; 2017 Jul; 65(1):100-106. PubMed ID: 28379314
[TBL] [Abstract][Full Text] [Related]
9. Comparative effectiveness of nafcillin or cefazolin versus vancomycin in methicillin-susceptible Staphylococcus aureus bacteremia.
Schweizer ML; Furuno JP; Harris AD; Johnson JK; Shardell MD; McGregor JC; Thom KA; Cosgrove SE; Sakoulas G; Perencevich EN
BMC Infect Dis; 2011 Oct; 11():279. PubMed ID: 22011388
[TBL] [Abstract][Full Text] [Related]
10. Tolerability of Cefazolin in Nafcillin-Intolerant Patients for the Treatment of Methicillin-Susceptible Staphylococcus aureus Infections.
Gandhi AM; Shah MD; Donohue LE; Cox HL; Eby JC
Clin Infect Dis; 2021 Nov; 73(9):1650-1655. PubMed ID: 33905485
[TBL] [Abstract][Full Text] [Related]
11. Does the Beta-Lactam Matter? Nafcillin versus Cefazolin for Methicillin-Susceptible Staphylococcus aureus Bloodstream Infections.
Burrelli CC; Broadbent EK; Margulis A; Snyder GM; Gold HS; McCoy C; Mahoney MV; Hirsch EB
Chemotherapy; 2018; 63(6):345-351. PubMed ID: 30965335
[TBL] [Abstract][Full Text] [Related]
12. Is cefazolin inferior to nafcillin for treatment of methicillin-susceptible Staphylococcus aureus bacteremia?
Lee S; Choe PG; Song KH; Park SW; Kim HB; Kim NJ; Kim EC; Park WB; Oh MD
Antimicrob Agents Chemother; 2011 Nov; 55(11):5122-6. PubMed ID: 21825299
[TBL] [Abstract][Full Text] [Related]
13. Comparison of the efficacy of nafcillin and glycopeptides as definitive therapy for patients with methicillin-susceptible Staphylococcus aureus bacteremia: a retrospective cohort study.
Oh DH; Kim JJ; Kim J; Seong H; Lee SJ; Kim YC; Kim EJ; Jung IY; Jeong WY; Jeong SJ; Ku NS; Han SH; Choi JY; Song YG; Kim JM
BMC Infect Dis; 2018 Jan; 18(1):60. PubMed ID: 29378565
[TBL] [Abstract][Full Text] [Related]
14. Tolerability of cefazolin after immune-mediated hypersensitivity reactions to nafcillin in the outpatient setting.
Blumenthal KG; Youngster I; Shenoy ES; Banerji A; Nelson SB
Antimicrob Agents Chemother; 2014 Jun; 58(6):3137-43. PubMed ID: 24637693
[TBL] [Abstract][Full Text] [Related]
15. Treatment outcomes with cefazolin versus oxacillin for deep-seated methicillin-susceptible Staphylococcus aureus bloodstream infections.
Rao SN; Rhodes NJ; Lee BJ; Scheetz MH; Hanson AP; Segreti J; Crank CW; Wang SK
Antimicrob Agents Chemother; 2015 Sep; 59(9):5232-8. PubMed ID: 26077253
[TBL] [Abstract][Full Text] [Related]
16. Implementation of a cefazolin-based stewardship pathway for methicillin-susceptible Staphylococcus aureus bloodstream infections paired with infectious diseases consultation.
Lee BJ; Rao SN; Wang SK; Lee JY; Lakada IY; Gilbert EM; Barr VO; Postelnick MJ; Sutton SH; Zembower TR; Bolon M; Scheetz MH; Rhodes NJ
Int J Antimicrob Agents; 2017 May; 49(5):650-654. PubMed ID: 28279787
[TBL] [Abstract][Full Text] [Related]
17. Comparative outcomes of cefazolin versus antistaphylococcal penicillins in methicillin-susceptible Staphylococcus aureus infective endocarditis: a post hoc analysis of a prospective multicentre French cohort study.
Lecomte R; Bourreau A; Deschanvres C; Issa N; Le Turnier P; Gaborit B; Chauveau M; Leroy AG; Le Tourneau T; Caillon J; Camou F; Boutoille D
Clin Microbiol Infect; 2021 Jul; 27(7):1015-1021. PubMed ID: 32950711
[TBL] [Abstract][Full Text] [Related]
18. Comparison of ceforanide, cefazolin, methicillin, and nafcillin in Staphylococcus aureus endocarditis therapy in rabbits.
Carrizosa J; Kobasa WD; Kaye D
Antimicrob Agents Chemother; 1980 Oct; 18(4):562-5. PubMed ID: 7447418
[TBL] [Abstract][Full Text] [Related]
19. Safety and Efficacy of Ceftriaxone in the Treatment of Methicillin-Susceptible
Ganguly A; de la Flor C; Alvarez K; Brown LS; Mang NS; Smartt J; King H; Perl TM; Filizola H; Bhavan KP
Ann Pharmacother; 2023 Apr; 57(4):425-431. PubMed ID: 35942602
[TBL] [Abstract][Full Text] [Related]
20. Outcomes of Ceftriaxone Compared With Cefazolin or Nafcillin/Oxacillin for Outpatient Therapy for Methicillin-Sensitive
Hamad Y; Nickel KB; Olsen MA; George IA
Open Forum Infect Dis; 2024 Feb; 11(2):ofad662. PubMed ID: 38352150
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
